COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine

Ann Rheum Dis. 2020 Oct;79(10):1382-1383. doi: 10.1136/annrheumdis-2020-217717. Epub 2020 May 12.
No abstract available

Keywords: epidemiology; hydroxychloroquine; lupus erythematosus, systemic.

Publication types

  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antirheumatic Agents / therapeutic use
  • Azathioprine / therapeutic use
  • Betacoronavirus
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques
  • Cohort Studies
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / physiopathology
  • Cough / physiopathology
  • Cyclosporine / therapeutic use
  • Diarrhea / physiopathology
  • Dysgeusia / physiopathology
  • Dyspnea / physiopathology
  • Fatigue / physiopathology
  • Female
  • Fever / physiopathology
  • Glucocorticoids / therapeutic use
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Intensive Care Units
  • Italy / epidemiology
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / epidemiology*
  • Male
  • Methotrexate / therapeutic use
  • Middle Aged
  • Mycophenolic Acid / therapeutic use
  • Olfaction Disorders / physiopathology
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / physiopathology
  • Prednisone / therapeutic use
  • Respiratory Distress Syndrome / epidemiology*
  • SARS-CoV-2
  • Telemedicine*

Substances

  • Antirheumatic Agents
  • Glucocorticoids
  • Immunosuppressive Agents
  • Hydroxychloroquine
  • Cyclosporine
  • Mycophenolic Acid
  • Azathioprine
  • Prednisone
  • Methotrexate